{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:34:25Z","timestamp":1790814865727,"version":"4.1.0"},"reference-count":170,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite pharmacological treatments and surgical practice options, the mortality rate of astrocytomas and glioblastomas remains high, thus representing a medical emergency for which it is necessary to find new therapeutic strategies. Fibroblast growth factors (FGFs) act through their associated receptors (FGFRs), a family of tyrosine kinase receptors consisting of four members (FGFR1\u20134), regulators of tissue development and repair. In particular, FGFRs play an important role in cell proliferation, survival, and migration, as well as angiogenesis, thus their gene alteration is certainly related to the development of the most common diseases, including cancer. FGFRs are subjected to multiple somatic aberrations such as chromosomal amplification of FGFR1; mutations and multiple dysregulations of FGFR2; and mutations, translocations, and significant amplifications of FGFR3 and FGFR4 that correlate to oncogenesis process. Therefore, the in-depth study of these receptor systems could help to understand the etiology of both astrocytoma and glioblastoma so as to achieve notable advances in more effective target therapies. Furthermore, the discovery of FGFR inhibitors revealed how these biological compounds improve the neoplastic condition by demonstrating efficacy and safety. On this basis, this review focuses on the role and involvement of FGFRs in brain tumors such as astrocytoma and glioblastoma.<\/jats:p>","DOI":"10.3390\/cancers12123825","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T04:12:01Z","timestamp":1608523921000},"page":"3825","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-0634","authenticated-orcid":false,"given":"Alessio","family":"Ardizzone","sequence":"first","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-9739","authenticated-orcid":false,"given":"Sarah A.","family":"Scuderi","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"Istituto Oncologico del Mediterraneo, Via Penninazzo 7, 95029 Viagrande (CT), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5395-8608","authenticated-orcid":false,"given":"Cristina","family":"Colarossi","sequence":"additional","affiliation":[{"name":"Istituto Oncologico del Mediterraneo, Via Penninazzo 7, 95029 Viagrande (CT), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-0082","authenticated-orcid":false,"given":"Caterina","family":"Puglisi","sequence":"additional","affiliation":[{"name":"IOM Ricerca Srl, Via Penninazzo 11, 95029 Viagrande (CT), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Campolo","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3690","authenticated-orcid":false,"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-6387","authenticated-orcid":false,"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Paterniti","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d\u2019Alcontres, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2277-9175.148261","article-title":"Brain tumors: Special characters for research and banking","volume":"4","author":"Kheirollahi","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","article-title":"The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision","volume":"57","author":"Komori","year":"2017","journal-title":"Neurol. Med. Chir."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/mrm.22147","article-title":"Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme","volume":"62","author":"Zacharaki","year":"2009","journal-title":"Magn. Reson. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-12-802997-8.00002-5","article-title":"Presenting signs and symptoms in brain tumors","volume":"134","author":"Alentorn","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0885066615619618","article-title":"Critical Care Management of Cerebral Edema in Brain Tumors","volume":"32","author":"Esquenazi","year":"2017","journal-title":"J. Intensive Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: Epidemiology, pathogenesis and management","volume":"139","author":"Chen","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.nic.2019.01.008","article-title":"Headache and Brain Tumor","volume":"29","author":"Hadidchi","year":"2019","journal-title":"Neuroimaging Clin. N. Am."},{"key":"ref_9","first-page":"211","article-title":"Primary Brain Tumors in Adults: Diagnosis and Treatment","volume":"93","author":"Perkins","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.11.003","article-title":"The activity of malignancy may determine stroke pattern in cancer patients","volume":"24","author":"Karlinska","year":"2015","journal-title":"J. Stroke Cereb. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ecp.11.1","article-title":"Corticosteroids in brain cancer patients: Benefits and pitfalls","volume":"4","author":"Dietrich","year":"2011","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01376517-200412000-00008","article-title":"Dexamethasone therapy in patients with brain tumors\u2014A focus on tapering","volume":"36","author":"Nahaczewski","year":"2004","journal-title":"J. Neurosci. Nurs."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"Wesseling","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair"},{"key":"ref_17","first-page":"555","article-title":"Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System","volume":"32","author":"Schreck","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.wneu.2016.04.011","article-title":"Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis","volume":"92","author":"Ma","year":"2016","journal-title":"World Neurosurg."},{"key":"ref_19","first-page":"CD011773","article-title":"Procarbazine, lomustine and vincristine for recurrent high-grade glioma","volume":"7","author":"Parasramka","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"Brandes","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1615\/CritRevOncog.2018025927","article-title":"Radiation and Brain Tumors: An Overview","volume":"23","author":"Grunert","year":"2018","journal-title":"Crit. Rev. Oncog."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.wneu.2017.04.041","article-title":"Extent of Resection in Glioma-A Review of the Cutting Edge","volume":"103","author":"Englander","year":"2017","journal-title":"World Neurosurg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2011.10.013","article-title":"Surgical treatment of brain metastasis: A review","volume":"114","author":"Mut","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sharma, P., and Debinski, W. (2018). Receptor-Targeted Glial Brain Tumor Therapies. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113326"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"reviews3005.1","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz","year":"2001","journal-title":"Genome Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"218142","DOI":"10.4061\/2010\/218142","article-title":"Fibroblast growth factors: Biology, function, and application for tissue regeneration","volume":"2010","author":"Yun","year":"2010","journal-title":"J. Tissue Eng."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.70.9.2702","article-title":"Pituitary extracts and steroid hormones in the control of 3T3 cell growth","volume":"70","author":"Armelin","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/249123a0","article-title":"Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth","volume":"249","author":"Gospodarowicz","year":"1974","journal-title":"Nature"},{"key":"ref_30","first-page":"163","article-title":"FGF signaling network in the gastrointestinal tract (review)","volume":"29","author":"Katoh","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/wound.2018.0853","article-title":"Tannic Acid Accelerates Cutaneous Wound Healing in Rats Via Activation of the ERK 1\/2 Signaling Pathways","volume":"8","author":"Chen","year":"2019","journal-title":"Adv. Wound Care (New Rochelle)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dai, S., Zhou, Z., Chen, Z., Xu, G., and Chen, Y. (2019). Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells, 8.","DOI":"10.3390\/cells8060614"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fcell.2020.00079","article-title":"FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency","volume":"8","author":"Quan","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/08977190009001069","article-title":"A soluble fibroblast growth factor receptor is released from HL-60 promyelocytic leukemia cells: Implications for paracrine growth control","volume":"17","author":"Wang","year":"2000","journal-title":"Growth Factors"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1042\/BST0340442","article-title":"Insights into the role of heparan sulphate in fibroblast growth factor signalling","volume":"34","author":"Harmer","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.abb.2017.06.002","article-title":"Evolution of the fusogenic activity of the receptor FGFRL1","volume":"625\u2013626","author":"Zhuang","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1042\/BST20180004","article-title":"Structure, activation and dysregulation of fibroblast growth factor receptor kinases: Perspectives for clinical targeting","volume":"46","author":"Farrell","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, F., Liang, X., Beaudet, J.M., Lee, Y., and Linhardt, R.J. (2014). The Effects of Metal Ions on Heparin\/Heparin Sulfate-Protein Interactions. J. Biomed. Technol. Res., 1.","DOI":"10.19104\/jbtr.2014.101"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"0589","DOI":"10.1098\/rsif.2015.0589","article-title":"Heparan sulfate and heparin interactions with proteins","volume":"12","author":"Meneghetti","year":"2015","journal-title":"J. R. Soc. Interface"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12964-019-0371-1","article-title":"Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins","volume":"17","author":"Kucinska","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.1105396","article-title":"Common and distinct elements in cellular signaling via EGF and FGF receptors","volume":"306","author":"Schlessinger","year":"2004","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.1038\/ncomms10262","article-title":"Mechanism of FGF receptor dimerization and activation","volume":"7","author":"Sarabipour","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/modpathol.2009.63","article-title":"Analysis of the fibroblastic growth factor receptor-RAS\/RAF\/MEK\/ERK-ETS2\/brachyury signalling pathway in chordomas","volume":"22","author":"Shalaby","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Latko, M., Czyrek, A., Porebska, N., Kucinska, M., Otlewski, J., Zakrzewska, M., and Opalinski, L. (2019). Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. Cells, 8.","DOI":"10.3390\/cells8050455"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1471-4159.2005.03284.x","article-title":"Structural biology of NCAM homophilic binding and activation of FGFR","volume":"94","author":"Kiselyov","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0092-8674(91)90569-K","article-title":"Morphoregulatory activities of NCAM and N-cadherin can be accounted for by G protein-dependent activation of L- and N-type neuronal Ca2+ channels","volume":"67","author":"Doherty","year":"1991","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0896-6273(94)90027-2","article-title":"Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin","volume":"13","author":"Williams","year":"1994","journal-title":"Neuron"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0896-6273(00)80264-0","article-title":"Expression of a dominant negative FGF receptor inhibits axonal growth and FGF receptor phosphorylation stimulated by CAMs","volume":"18","author":"Saffell","year":"1997","journal-title":"Neuron"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.1523\/JNEUROSCI.18-24-10429.1998","article-title":"Neurite outgrowth stimulated by neural cell adhesion molecules requires growth-associated protein-43 (GAP-43) function and is associated with GAP-43 phosphorylation in growth cones","volume":"18","author":"Meiri","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1471-4159.2000.0750665.x","article-title":"Neurite outgrowth induced by a synthetic peptide ligand of neural cell adhesion molecule requires fibroblast growth factor receptor activation","volume":"75","author":"Ronn","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1083\/jcb.200109059","article-title":"Cosignaling of NCAM via lipid rafts and the FGF receptor is required for neuritogenesis","volume":"157","author":"Niethammer","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/mcne.1996.0049","article-title":"CAM-FGF receptor interactions: A model for axonal growth","volume":"8","author":"Doherty","year":"1996","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000014630","article-title":"N-cadherin-mediated cell contact regulates ovarian surface epithelial cell survival","volume":"9","author":"Peluso","year":"2000","journal-title":"Biol. Signals Recept."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yexcr.2003.11.033","article-title":"Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: Involvement of fibroblast growth factor receptor-mediated signalling","volume":"294","author":"Erez","year":"2004","journal-title":"Exp. Cell Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1535-6108(02)00150-2","article-title":"A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor","volume":"2","author":"Suyama","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/35083041","article-title":"N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling","volume":"3","author":"Cavallaro","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/er.2003-0040","article-title":"Fibroblast growth factor signaling during early vertebrate development","volume":"26","author":"Bottcher","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejcb.2016.05.002","article-title":"N-Cadherin and Fibroblast Growth Factor Receptors crosstalk in the control of developmental and cancer cell migrations","volume":"95","author":"Nguyen","year":"2016","journal-title":"Eur. J. Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/0008-5472.CAN-06-3401","article-title":"N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation","volume":"67","author":"Hulit","year":"2007","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1038\/onc.2013.310","article-title":"N-cadherin\/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem\/progenitor cell-like properties","volume":"33","author":"Qian","year":"2014","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.tips.2015.08.004","article-title":"L1-CAM and N-CAM: From Adhesion Proteins to Pharmacological Targets","volume":"36","author":"Colombo","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tins.2017.03.003","article-title":"Neural Cell Adhesion Molecules of the Immunoglobulin Superfamily Regulate Synapse Formation, Maintenance, and Function","volume":"40","author":"Sytnyk","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35208","DOI":"10.1074\/jbc.M608655200","article-title":"The fibroblast growth factor receptor acid box is essential for interactions with N-cadherin and all of the major isoforms of neural cell adhesion molecule","volume":"281","author":"Howell","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200903030","article-title":"The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking","volume":"187","author":"Francavilla","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.febslet.2006.05.008","article-title":"The neural cell adhesion molecule binds to fibroblast growth factor receptor 2","volume":"580","author":"Christensen","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1242\/jcs.010744","article-title":"Neural cell adhesion molecule regulates the cellular response to fibroblast growth factor","volume":"120","author":"Francavilla","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Amoureux, M.C., Coulibaly, B., Chinot, O., Loundou, A., Metellus, P., Rougon, G., and Figarella-Branger, D. (2010). Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-91"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuron.2007.01.009","article-title":"Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma","volume":"53","author":"Ligon","year":"2007","journal-title":"Neuron"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mcn.2006.05.009","article-title":"Anosmin-1 modulates the FGF-2-dependent migration of oligodendrocyte precursors in the developing optic nerve","volume":"33","author":"Bribian","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.expneurol.2010.01.006","article-title":"Dynamic roles of FGF-2 and Anosmin-1 in the migration of neuronal precursors from the subventricular zone during pre- and postnatal development","volume":"222","author":"Clemente","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1471-4159.2010.07024.x","article-title":"Biochemical dissection of Anosmin-1 interaction with FGFR1 and components of the extracellular matrix","volume":"115","author":"Esteban","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10585-012-9555-4","article-title":"L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor","volume":"30","author":"Mohanan","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40478-020-00898-6","article-title":"FGFR- gene family alterations in low-grade neuroepithelial tumors","volume":"8","author":"Bale","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"14344","DOI":"10.1073\/pnas.0507200102","article-title":"Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas","volume":"102","author":"Rand","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.1816","article-title":"Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: Investigating a potential link","volume":"207","author":"Hansen","year":"2005","journal-title":"J. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","article-title":"High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer","volume":"83","author":"Preusser","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","article-title":"Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)","volume":"43","author":"Freier","year":"2007","journal-title":"Oral Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/1078-0432.CCR-07-0502","article-title":"High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications","volume":"13","author":"Gorringe","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_88","first-page":"4514","article-title":"High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer","volume":"61","author":"Simon","year":"2001","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/gcc.20655","article-title":"Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development","volume":"48","author":"Missiaglia","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: A review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Jung","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ng2075","article-title":"A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer","volume":"39","author":"Hunter","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1158\/0008-5472.CAN-13-3218","article-title":"Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC","volume":"74","author":"Tchaicha","year":"2014","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/0008-5472.CAN-14-3771","article-title":"Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2","volume":"75","author":"Tanizaki","year":"2015","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: Cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, S.Q., Cheuk, A.T., Shern, J.F., Song, Y.K., Hurd, L., Liao, H., Wei, J.S., and Khan, J. (2013). Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076551"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-04-0408","article-title":"The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression","volume":"10","author":"Wang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_101","first-page":"840","article-title":"Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele","volume":"62","author":"Bange","year":"2002","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: A \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma Subclassifications and Their Clinical Significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2017.11.010","article-title":"Glioma epigenetics: From subclassification to novel treatment options","volume":"51","author":"Gusyatiner","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00428-017-2181-4","article-title":"Characterization of gliomas: From morphology to molecules","volume":"471","author":"Ferris","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"45","author":"Frattini","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_112","unstructured":"Kapoor, M., and Gupta, V. (2020). Astrocytoma. StatPearls, StatPearls Publishing."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.1190928","article-title":"Specification and morphogenesis of astrocytes","volume":"330","author":"Freeman","year":"2010","journal-title":"Science"},{"key":"ref_114","unstructured":"Stanfield, C.L., Germann, W.J., Niles, M.J., and Cannon, J.G. (2011). Principles of Human Physiology, Benjamin Cummings USA."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: Genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008\u20132012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/0883073809342005","article-title":"Pediatric low-grade gliomas","volume":"24","author":"Sievert","year":"2009","journal-title":"J. Child. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1002\/jcp.27193","article-title":"A systemic insight into astrocytoma biology across different grades","volume":"234","author":"Chakraborty","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3892\/mmr.2016.5061","article-title":"Expression patterns of Wnt signaling component, secreted frizzledrelated protein 3 in astrocytoma and glioblastoma","volume":"13","author":"Kafka","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1002\/cncr.31039","article-title":"Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications","volume":"123","author":"Miller","year":"2017","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors","volume":"372","author":"Lachance","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"ra6","DOI":"10.1126\/scisignal.2000021","article-title":"The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations","volume":"2","author":"Lew","year":"2009","journal-title":"Sci Signal."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4297","article-title":"Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours","volume":"232","author":"Parker","year":"2014","journal-title":"J. Pathol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sie, M., den Dunnen, W.F., Lourens, H.J., Meeuwsen-de Boer, T.G., Scherpen, F.J., Zomerman, W.W., Kampen, K.R., Hoving, E.W., and de Bont, E.S. (2015). Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122555"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-019-03306-9","article-title":"Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas","volume":"145","author":"Trisolini","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Lehtinen, B., Raita, A., Kesseli, J., Annala, M., Nordfors, K., Yli-Harja, O., Zhang, W., Visakorpi, T., Nykter, M., and Haapasalo, H. (2017). Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3274-9"},{"key":"ref_133","first-page":"1206","article-title":"Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas","volume":"19","author":"Granberg","year":"2017","journal-title":"Neuro Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature25171","article-title":"A metabolic function of FGFR3-TACC3 gene fusions in cancer","volume":"553","author":"Frattini","year":"2018","journal-title":"Nature"},{"key":"ref_135","first-page":"475","article-title":"FGFR-TACC gene fusions in human glioma","volume":"19","author":"Lasorella","year":"2017","journal-title":"Neuro Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/07357907.2011.630050","article-title":"Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets","volume":"30","author":"Mao","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ajco.12756","article-title":"Biomarkers and therapeutic advances in glioblastoma multiforme","volume":"14","author":"Sasmita","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fsurg.2016.00011","article-title":"Immune Evasion Strategies of Glioblastoma","volume":"3","author":"Razavi","year":"2016","journal-title":"Front. Surg."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-015-1716-2","article-title":"Current challenges in designing GBM trials for immunotherapy","volume":"123","author":"Weathers","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/neuonc\/4.4.278","article-title":"Epidemiology of primary brain tumors: Current concepts and review of the literature","volume":"4","author":"Wrensch","year":"2002","journal-title":"Neuro Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: A clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: Pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1007\/s12035-018-0880-8","article-title":"Reactive Astrocytes in Glioblastoma Multiforme","volume":"55","author":"Guan","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jmoldx.2011.06.003","article-title":"Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays","volume":"13","author":"Crespo","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1593\/neo.05307","article-title":"Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment","volume":"7","author":"Wemmert","year":"2005","journal-title":"Neoplasia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11670-002-0013-8","article-title":"Chromosome 17P may harbor multiple tumor suppressor genes associated with primary glioblastoma multiforme","volume":"14","author":"Hu","year":"2002","journal-title":"Chin. J. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Jimenez-Pascual, A., and Siebzehnrubl, F.A. (2019). Fibroblast Growth Factor Receptor Functions in Glioblastoma. Cells, 8.","DOI":"10.3390\/cells8070715"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.seminoncol.2015.09.027","article-title":"Fibroblast Growth Factor (FGF) Receptor\/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors","volume":"42","author":"Hierro","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tcb.2008.06.005","article-title":"The TACC proteins: TACC-ling microtubule dynamics and centrosome function","volume":"18","author":"Peset","year":"2008","journal-title":"Trends Cell Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: Mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-030-30651-9_7","article-title":"Signaling Determinants of Glioma Cell Invasion","volume":"1202","author":"Kwiatkowska","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_154","first-page":"9274016","article-title":"The Role of Rho GTPases in Motility and Invasion of Glioblastoma Cells","volume":"2020","author":"Atat","year":"2020","journal-title":"Anal. Cell. Pathol."},{"key":"ref_155","first-page":"243","article-title":"Increased expression of genes from growth factor signaling pathways in glioblastoma cell lines","volume":"7","author":"Saxena","year":"1992","journal-title":"Oncogene"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01063768","article-title":"Suramin inhibits glioma cell proliferation in vitro and in the brain","volume":"21","author":"Takano","year":"1994","journal-title":"J. Neurooncol."},{"key":"ref_157","first-page":"419","article-title":"Autocrine factors sustain glioblastoma stem cell self-renewal","volume":"21","author":"Li","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1038\/onc.2008.61","article-title":"FGF5 as an oncogenic factor in human glioblastoma multiforme: Autocrine and paracrine activities","volume":"27","author":"Allerstorfer","year":"2008","journal-title":"Oncogene"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"118842","DOI":"10.1016\/j.ijpharm.2019.118842","article-title":"P-glycoprotein (ABCB1\/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554)","volume":"573","author":"Li","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Andre, F., Ranson, M., Dean, E., Varga, A., Van der Noll, R., Stockman, P.K., Ghiorghiu, D., Kilgour, E., Smith, P.D., and Macpherson, M. (2013, January 6\u201310). Abstract LB-145: Results of a Phase I Study of AZD4547, an Inhibitor of Fibroblast Growth Factor Receptor (FGFR), in Patients with Advanced Solid Tumors. Proceedings of the AACR 104th Annual Meeting 2013, Washington, DC, USA.","DOI":"10.1158\/1538-7445.AM2013-LB-145"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-12-0999","article-title":"Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells","volume":"12","author":"Konecny","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3825\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:46:49Z","timestamp":1760179609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":170,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123825"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123825","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}